Advocate for the Pathologist Within the MDT

Before advancing to this final program in the five-part masterclass series, make sure to complete the previous program by clicking here.

There are over 90 FDA-approved, precision oncology treatments that involve biomarker testing considerations for eligible patients with cancer.¹ So why are some patients still not receiving these precision oncology treatments for which they may otherwise be eligible? Uncover some reasons why in the third module of this Precision Medicine Masterclass, featuring Dr. Michael Overman, Oncologist and Professor at The University of Texas MD Anderson Cancer Center in Houston, Texas, and Dr. Anil Parwani, Anatomical Pathologist at The Ohio State University Wexner Medical Center in Columbus, Ohio.

MDT = multidisciplinary team.

Reference:

1. Sadik H et al. JCO Precis Oncol. 2022;6:e2200246.